These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25295402)

  • 1. Drug plan design incentives among Medicare prescription drug plans.
    Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
    Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
    Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
    Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of COPD inhaler coverage in Medicare Part D.
    Wormser B; Socal MP; Anderson G
    Am J Manag Care; 2021 May; 27(5):187-193. PubMed ID: 34002960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region.
    Chinthammit C; Bhattacharjee S; Axon DR; Slack M; Bentley JP; Warholak TL; Wilson DL; Lo-Ciganic WH
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1309-1316. PubMed ID: 32996396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries.
    Gilman BH; Kautter J
    Health Serv Res; 2008 Apr; 43(2):478-95. PubMed ID: 18370964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
    Cubanski J; Neuman P
    Health Aff (Millwood); 2007; 26(1):w1-12. PubMed ID: 17118944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficiary price sensitivity in the Medicare prescription drug plan market.
    Frakt AB; Pizer SD
    Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare Prescription Drug Plan Enrollees Report Less Positive Experiences Than Their Medicare Advantage Counterparts.
    Elliott MN; Landon BE; Zaslavsky AM; Edwards C; Orr N; Beckett MK; Mallett J; Cleary PD
    Health Aff (Millwood); 2016 Mar; 35(3):456-63. PubMed ID: 26953300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attribute substitution in early enrollment decisions into Medicare prescription drug plans.
    Frakt AB; Pizer SD
    Health Econ; 2008 Apr; 17(4):513-21. PubMed ID: 17935198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?
    Walberg MP; Patel RA
    J Am Pharm Assoc (2003); 2009; 49(6):777-82. PubMed ID: 19926558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.